Astrazeneca (AZN) Operating Leases (2018 - 2026)

Astrazeneca has reported Operating Leases for 9 years, with the latest figure at -$426.0 million in Q2 2026.

• On a quarterly basis, Operating Leases fell 18.01% year-over-year to -$426.0 million in Q2 2026; TTM through Jun 2026 was -$426.0 million, a 18.01% decrease from a year earlier, with the FY2025 full-year figure at -$382.0 million, down 12.68% from the prior year.
• Operating Leases was -$426.0 million for Q2 2026 at Astrazeneca, down from -$383.0 million in the prior quarter.
• The five-year high for Operating Leases was -$210.0 million in Q3 2022, with the low at -$426.0 million in Q2 2026.
• Average Operating Leases over 5 years is -$298.2 million, with a median of -$286.5 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Operating Leases rose 8.3% in 2022, then slumped 34.89% in 2024.
• Over 5 years, Operating Leases stood at -$228.0 million in 2022, then decreased by 18.86% to -$271.0 million in 2023, then declined by 25.09% to -$339.0 million in 2024, then dropped by 12.68% to -$382.0 million in 2025, then retreated by 11.52% to -$426.0 million in 2026.
• The last three Operating Leases figures came in at -$426.0 million (Q2 2026), -$383.0 million (Q1 2026), and -$382.0 million (Q4 2025), per Business Quant data.